Casinos Not On Gamstop UK

Facebook Twitter LinkedIn

Home Back Issues Category Clinical Trial eAlert Articles

Category >> Clinical Trial eAlert Articles
Aug 16
2010

No. 12: PI Bears Heavy Responsibility in Medical-Device Study

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
Jul 19
2010

No. 11: Why it's best to respond in writing to FDA's Form 483

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
Jul 12
2010

No. 10: Is an IND necessary for pregabalin and paclitaxel studies

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
Jul 05
2010

No. 9: What to do when the researcher is the only study subject

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
Jun 28
2010

No. 8: Who is responsible for an IND annual report?

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
Jun 21
2010

No. 7: When is an IND necessary?

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
Jun 14
2010

No 6: Conducting a Multi-Site Trial with Individual IND Applications

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
Jun 07
2010

No 5: Why It's Best to Cooperate with an Unannounced FDA Inspection

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
May 31
2010

No. 4: Does Study of Botanical Product Require an IND?

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
May 24
2010

No. 3: Marketed drug for cancer treatment

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
May 17
2010

No 2: Medical Practice vs. Clinical Research

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged 
May 10
2010

No 1: Faulty Transfer Triggers IND Termination

Posted by: PIA in Clinical Trial eAlert Articles

Tagged in: Untagged